Hims, Hers and Preventive healthcare

Why Hims & Hers Health Stock Is Plummeting Today
Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as much as 26.1% earlier in the day. The move comes as the S&P 500 lost 1% and the Nasdaq Composite lost 1.
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic supply chain and meet rising demand for personalized medications. The deal’s terms were not disclosed.
Why Is HIMS Stock Down So Much? Should You Buy?
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which previously allowed Hims & Hers to sell compounded alternatives. Compounded versions were permitted during the shortage but are now restricted unless they meet specific exceptions.
Hims and Hers Stock Drops Weight as Earnings Loom
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings
Hims & Hers Health Stock: A Millionaire-Maker in the Making?
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers is a healthcare giant with millions of users. If that happens, I don't doubt the stock could change lives, even after its epic run thus far.
Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers Acquires US-based Peptide Facility
Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s long-term ability to deliver personalized medications.
Hims & Hers: A Glorious Opportunity To Trim (Rating Downgrade)
Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...
Leerink sees potential for ‘reset’ in Hims & Hers with Ozempic shortage ended
Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.
Why Hims & Hers Health Stock Is Skyrocketing Today
Shares of Hims & Hers Health Inc ( HIMS 17.50%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p ...
Hims & Hers to offer at-home blood draws, lean into 'peptide innovations' with new acquisitions
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
Hims & Hers: The Pros And Cons Of The Trybe Acquisition
Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...
Hims & Hers Stock Hits Record High on Blood-Testing Lab Acquisition
Key Takeaways Shares of Hims & Hers Health touched a fresh record high in Wednesday trading after the company announced its ...